VERONA PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.1 USD | -1.83% |
|
-0.43% | -19.01% |
| Sales 2024 * | 19.95M 24.83M | Sales 2025 * | 103M 129M | Capitalization | 1.05B 1.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -80M -99.56M | Net income 2025 * | -38M -47.29M | EV / Sales 2024 * | 43.2 x |
| Net cash position 2024 * | 184M 229M | Net cash position 2025 * | 146M 182M | EV / Sales 2025 * | 8.71 x |
| P/E ratio 2024 * |
-26.9
x | P/E ratio 2025 * |
-84.7
x | Employees | 79 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Verona Pharma plc
More recommendations
More press releases
| 1 day | -1.83% | ||
| 1 week | -0.43% | ||
| Current month | +0.06% | ||
| 1 month | +3.67% | ||
| 3 months | -6.29% | ||
| 6 months | +19.35% | ||
| Current year | -19.01% |
1 week
15.75
16.57
1 month
15.1117.25
Current year
15.1120.67
1 year
11.8323.81
3 years
3.4126.44
5 years
0.0026.44
10 years
0.0026.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 16.1 | -1.83% | 490,010 |
| 24-04-17 | 16.4 | +1.23% | 348,627 |
| 24-04-16 | 16.2 | +2.53% | 547,642 |
| 24-04-15 | 15.8 | -0.69% | 321,867 |
| 24-04-12 | 15.91 | -1.61% | 667,111 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.1
USD
Average target price
33.86
USD
Spread / Average Target
+110.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.01% | 1.3B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.48% | 21.66B | |
| -18.35% | 20.77B | |
| -8.93% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- VRNA Stock
